http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Won, Hoyoun,Kim, Jung-Sun,Shin, Dong-Ho,Kim, Byeong-Keuk,Ko, Young-Guk,Choi, Donghoon,Jang, Yangsoo,Hong, Myeong-Ki Hindawi Publishing Corporation 2014 BioMed research international Vol.2014 No.-
<P><I>Purposes</I>. The serial changes in neointimal tissues were compared between everolimus-eluting stent (EES) and bare-metal stent (BMS) in the porcine coronary artery using optical coherence tomography (OCT). <I>Methods</I>. Serial (1, 3, and 6 month follow-up after stent implantation) OCT examinations were performed in 15 swine with 15 BMS- and 15 EES-treated lesions in porcine coronary arteries. <I>Results</I>. In BMS-implanted lesions, neointimal volume decreased from 7.3 mm<SUP>3</SUP> to 6.9 mm<SUP>3</SUP> and 6.4 mm<SUP>3</SUP> at 1, 3, and 6 months follow-up without statistical significance (<I>P</I> = 0.369). At the time points of 1, 3, and 6 months, neointimal tissue appearance was mainly a homogeneous pattern (80.0%, 93.3%, and 100%, resp.), while the other pattern was layered. In contrast, in EES-implanted lesions, neointimal volume significantly increased from 4.8 mm<SUP>3</SUP> to 9.8 mm<SUP>3</SUP> between 1 and 3 months but significantly decreased to 8.6 mm<SUP>3</SUP> between 3 and 6 months (<I>P</I> < 0.001). Between 1 and 3 months, the layered pattern of neointimal tissue increased from 26.7% to 66.7% but decreased to 20.0% between 3 and 6 months. <I>Conclusions</I>. EES had a biphasic pattern of neointimal amounts that correlated with changes in neointimal morphology.</P>
Gwang Sil Kim,Young-Guk Ko,Yongsung Suh,Hoyoun Won,Sung-Jin Hong,Chul-Min Ahn,Jung-Sun Kim,Byeong-Keuk Kim,Donghoon Choi,Myeong-Ki Hong,Yangsoo Jang 대한심장학회 2020 Korean Circulation Journal Vol.50 No.11
Background and Objectives: The effectiveness of angiotensin II receptor blockers (ARBs) compared with angiotensin converting enzyme inhibitors (ACEIs) in patients with acute myocardial infarction (AMI) has not been established. We investigated the effects of ARBs on clinical outcomes after percutaneous coronary intervention (PCI) in AMI patients. Methods: Patients receiving ACEIs or ARBs after AMI treated with PCI between January 2005 and December 2014 were selected from the Korean National Health Insurance Service database. The primary endpoint was major cardiovascular adverse event (MACE; all-cause death, myocardial infarct [MI], or stroke). Results: We included patients regularly taking ACEIs (n=22,331) or ARBs (n=28,533) (medication possession ratio ≥80%). Compared with the ACEI group, the ARB group contained more females (31% vs. 18%), were older (mean, 63 vs. 60 years), and had more comorbidities, including hypertension (62.8% vs. 44.8%), diabetes (33.9% vs. 26.4%), congestive heart failure (7.9% vs. 4.3%), chronic obstructive pulmonary disease (25.5% vs. 18.9%), and end-stage renal disease (1.3% vs. 0.4%) (p<0.001 for all). After propensity score–matching, ARBs were associated with a 23% lower risk of MACE (hazard ratio [HR], 0.774; 95% confidence interval [CI], 0.715–0.838; p<0.001) than ACEIs. ARB use was also associated with a significantly reduced risk of death (HR, 0.741; 95% CI, 0.659–0.834; p<0.001), MI (HR, 0.731; 95% CI, 0.638–0.837; p<0.001), and revascularization (HR, 0.816; 95% CI, 0.773–0.861; p<0.001). Conclusions: ARB use was associated with a lower risk of MACE, MI, and revascularization than ACEIs in our retrospective analysis of AMI patients who underwent PCI.
Gyu Tae Park,Moonki Jung,Young Kim,Iksung Cho,Hoyoun Won,Seung Yong Shin,Wang-Soo Lee,Kwang Je Lee,Sang-Wook Kim,Tae Ho Kim,김치정 한국지질동맥경화학회 2017 지질·동맥경화학회지 Vol.7 No.2
Objective: Previous studies have shown that fenofibrate therapy increases serum creatinine level and that there is a returnof serum creatinine to baseline level after the discontinuation of the drug. We evaluated the effect of long-term fenofibratetherapy on creatinine levels and its reversibility in patients with hypertension and hypertriglyceridemia. Methods: This retrospective study enrolled 54 hypertensive and hypertriglyceridemic patients taking fenofibrate for 3-6years (Fenofibrate group) and 30 control patients with similar age, sex, follow-up duration, and creatinine levels (Controlgroup). In 23 patients taking fenofibrate with low triglyceride level and/or with high creatinine levels, fenofibrate was discontinued,and creatinine levels were measured after 2 months. Results: Creatinine levels increased in both the fenofibrate group (from 0.91±0.18 mg/dL to 1.09±0.23 mg/dL, p<0.001)and the control group (from 0.94±0.16 mg/dL to 0.98±0.16 mg/dL, p=0.04) compared to baseline. However, the elevationwas more pronounced in the fenofibrate group than in the control group (21.1±15.4% vs. 4.5±11.3%, p<0.001). Thediscontinuation of fenofibrate lowered creatinine levels (from 1.39±0.32 mg/dL to 1.15±0.24 mg/dL, p<0.001) whichwere still higher than pre-treatment levels (p=0.013). Conclusion: Long-term fenofibrate therapy significantly increased creatinine levels in hypertensive and hypertriglyceridemicpatients. The effect of fenofibrate on creatinine level was partially reversible. This finding suggests that follow-up creatininelevel is necessary with fenofibrate therapy. (J Lipid Atheroscler 2017 December;6(2):89-96)
Min Jae Cha,William D Kim,Hoyoun Won,Jaeeun Joo,Hasung Kim,In-Cheol Kim,Jin Young Kim,Seonhwa Lee,Iksung Cho 대한심장학회 2022 Korean Circulation Journal Vol.52 No.11
Background and Objectives: Real-world trends in the utility and type of gatekeeping studies in invasive coronary angiography (ICA) requires further investigation. Methods: We identified outpatients who underwent noninvasive cardiac tests or directly ICA for suspected coronary artery disease (CAD) from the nationwide Korea Health Insurance Review and Assessment Service-National Patient Sample database between 2012 and 2018. Results: Among 71,401 patients, the percentage of patients who were evaluated for suspected CAD was 34.7% for treadmill test (TMT), 4.2% for single-photon emission computed tomography (SPECT), 24.2% for coronary computed tomography angiography (CCTA), 1.6% for multiple gatekeepers, and 32.3% for directly ICA without noninvasive studies. The proportion of CCTA as a gatekeeper showed linear increase, (18.6% in 2012 and 28.8% in 2018; p<0.001), while those of TMT, SPECT, and direct ICA have decreased (p<0.001, p=0.03, and p<0.001, respectively). The overall incidence of downstream ICA after gatekeeper was 13.8% (6,662/48,346), and SPECT showed higher ICA rate in pairwise comparison with TMT and CCTA (p<0.001). Patients who performed gatekeepers before ICA showed higher rate of subsequent PCI (34.7% vs. 32.3%; p<0.001) and CABG (3.5% vs. 1.0%; p<0.001), compared to those who directly underwent ICA, and CCTA was associated with higher revascularization rate after ICA in pairwise comparison with TMT and SPECT (p<0.001). Conclusions: Nationwide database demonstrated that CCTA is utilized increasingly as a gatekeeper for ICA and is associated with high revascularization rate after ICA in outpatients with suspected CAD.
Five-Year Clinical Outcomes of Copeptin in patient with ST elevation Acute Myocardial I nfarction
( Moon Ki Jung ),( Jee Eun Kwon ),( Seong Hyeop Hyeon ),( Young Kim ),( Hoyoun Won ),( Seung Yong Shin ),( Wang Soo Lee ),( Kwang Je Lee ),( Sang Wook Kim ),( Tae Ho Kim ),( Chee Jeong Kim ) 대한내과학회 2015 대한내과학회 추계학술발표논문집 Vol.2015 No.1
We collected 111 coronary arterial blood samples at the coronary artery ostium during primary percutaneous coronary intervention(PCI) in STEMI and assessed the clinical outcomes depending on Copeptin. We evaluated cardiac biomarkers[CK, CK-MB, troponin-I, CRP] and additionally measured the recently introduced biomarkers [Copeptin(C-terminal Provasopressin), N-terminal pro-B-type natriuretic peptide(NT-proBNP)]. Intravascular ultrasound (IVUS) imaging was performed before and after stent implantation during primary PCI. Results: Pt age was 59±12 yrs and 86% were male. STEMI pts had a higher copeptin level than normal pts(243.31±169.68 pmol/L in vs 18.14±6.17 pmol/L, p=0.010). NT-proBNP was not correlated with copeptin (r=0.183, p=0.085). IVUS analysis of the culprit lesion showed the ruptured plaque in 47%(40/86 pts). VH-TCFA was identified in 36 patients, however, the mean copeptin level was similar compared to non-VH-TCFA pts(292.62±199.77 pmol/L vs 240.78±189.46 pmol/L, p=0.328). In hospital death occurred in 7 pts who showed higher Copeptin level than survivors. All were due to cardiogenic shock after primary PCI. The level of Copeptin was higher in-hospital death group than survivor(382.7±263 pmol/L vs. 211.3±127 pmol/L, p=0.0001). The clinical outcomes was worse in pts with Copeptin ≥300 pmol/L during five years follow up (p=0.046). Conclusions: Stress stimulated Copeptin might be one of the prognostic marker in long-term outcomes of STEMI. Thepotential role of Copeptin deserves to confirm with a further study.
Hoyoun Won,Yongsung Suh,Gwang Sil Kim,Young-Guk Ko,Myeong-Ki Hong 대한심장학회 2020 Korean Circulation Journal Vol.50 No.6
Background and Objectives: Whether beta blockers favorably impact the clinical outcome in patients with acute myocardial infarction (AMI) remains in debate. We investigated the impact of beta blocker on major clinical outcomes during 2 years after percutaneous coronary intervention (PCI) in patients with AMI. Methods: All patients with the first AMI treated with PCI for the period of 2005 to 2014 from the Korean National Health Insurance Service claims database were enrolled. We defined the regular user as medication possession ratio (MPR) ≥80% and non-user as MPR=0%. We compared the occurrence of all cause death, myocardial infarction (MI) and stroke according to adherence of beta-blockers. A 1:1 propensity score-matching was conducted to adjust for between-group differences. Results: We identified a total 81,752 patients with met eligible criteria. At discharge, 63,885 (78%) patients were prescribed beta blockers. For 2 years follow up period, regular users were 53,991 (66%) patients, non-users were 10,991 (13%). In the propensity score matched population, regular use of beta blocker was associated with a 36% reduced risk of composite adverse events (all death, MI or stroke) (hazard ratio [HR], 0.636; 95% confidence interval [CI], 0.555–0.728; p<0.001). Compared to no use of beta blocker, regular use significantly reduced all death (HR, 0.736; 95% CI, 0.668–0.812; p<0.001), MI (HR, 0.729; 95% CI, 0.611–0.803; p<0.001) and stroke (HR, 0.717; 95% CI, 0.650–0.791; p<0.001). Conclusions: Prescription of beta blocker in patients with AMI after PCI was sequentially increased. Continuous regular use of beta blocker for 2 years after AMI reduced major adverse events compared to no use of beta blocker.